About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

UNKNOWNNCT05181774

Prediction of Bleeding Risk After Anticoagulant Therapy for Atrial Fibrillation Based on Proteomics and Metabolomics

Objectives: Atrial fibrillation (AF) is the most common arrhythmia. Anticoagulation with warfarin or new oral anticoagulants in patients with AF can significantly reduce thromboembolic events. However...

Lead sponsor: Yue LI•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Haiyu Zhang, MD

CONTACT

+8645185555009 [email protected]

Sponsors

Lead Sponsor

Yue LI

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Age 18 years or above
•2. Admission with atrial fibrillation or clinic visit for atrial fibrillation
•3. Receive routine anticoagulant therapy;
•4. Signing the consent form

Exclusion Criteria

•1. Pregnant women;
•2. Lactating women;
•3. Severe mitral stenosis;
•4. Severe impairment of liver function;
•5. Severe renal insufficiency;
•6. Thyroid dysfunction requiring treatment;
•7. Have a history of severe bleeding within five years, such as intracerebral hemorrhage and gastrointestinal bleeding.

Related studies

Hormonal Management of Heavy Menstrual Bleeding in Adolescents

NCT06740929 · Heavy Menstrual Bleeding, Bleeding Disorder

CLOT-LESS - CLOsure Tailored: LEss Antithrombotic Strategy After LAAC for Stroke Prevention

NCT07575867 · Atrial Fibrillation, Stroke Prevention in Patients With Atrial Fibrillation, and more

Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation)

NCT05454787 · Life Threatening Bleeding, Factor Xa Inhibitor

Timing of Resumption of Direct Oral Anticoagulants Following Polypectomy

NCT06482333 · Postpolypectomy Bleeding

PROSPective Evaluation of Outcome After CatheTer Ablation in Atrial Fibrillation

NCT05009797 · Atrial Fibrillation

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: January 6, 2022Terms

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment100

Start dateDec 2021

Last updatedJan 6, 2022

Condition

Atrial Fibrillation Bleeding Anticoagulant Therapy

Locations shown

Yan

Harbin, Heilongjiang

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 6, 2022Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions